• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc

    5/14/25 10:47:09 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    IMMUNOCORE HOLDINGS PLC-ADR

    (Name of Issuer)


    ADR

    (Title of Class of Securities)


    45258D105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45258D105


    1Names of Reporting Persons

    T. Rowe Price Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MARYLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,051,818.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,051,818.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,051,818.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IMMUNOCORE HOLDINGS PLC-ADR
    (b)Address of issuer's principal executive offices:

    90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, X0, OX14 4RY
    Item 2. 
    (a)Name of person filing:

    T. Rowe Price Investment Management, Inc.
    (b)Address or principal business office or, if none, residence:

    1307 Point Street, Baltimore, MD 21231
    (c)Citizenship:

    Maryland
    (d)Title of class of securities:

    ADR
    (e)CUSIP No.:

    45258D105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    7051818
    (b)Percent of class:

    14.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    7051818

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    7051818

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    T. Rowe Price Investment Management, Inc.
     
    Signature:Ellen York
    Name/Title:Vice President
    Date:05/14/2025
    Get the next $IMCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    5/27/2025$65.00Buy
    Deutsche Bank
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    11/2/2023Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Immunocore with a new price target

      Deutsche Bank initiated coverage of Immunocore with a rating of Buy and set a new price target of $65.00

      5/27/25 9:10:28 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

      12/13/24 8:04:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Mizuho with a new price target

      Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously

      11/11/24 7:41:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

      RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (NASDAQ:IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in Turkey and across the Middle East, North Africa, Caucasus and the Commonwealth of Independent States (CIS) regions. Immunocore is a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically i

      6/30/25 8:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at the 2025 Jefferies Global Healthcare Conference

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare ConferenceFireside Chat: Thursday, June 5, 2025, at 11:05 a.m. EDT The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations', under ‘Events', via the ‘Investors' s

      6/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    SEC Filings

    See more
    • Immunocore Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      5/15/25 4:12:40 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc

      SCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      5/14/25 10:47:09 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc

      SCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      5/12/25 10:44:44 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pao William

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      5/19/25 4:15:17 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Ratcliffe Peter John

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      5/19/25 4:15:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bell John Irving

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      5/19/25 4:15:09 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:28:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:22:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 6:40:08 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunocore Appoints Siddharth Kaul to its Board of Directors

      Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

      6/9/22 7:45:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Financials

    Live finance-specific insights

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

      KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase

      2/26/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u

      2/19/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care